Loading color scheme


Scioto Biosciences Doses First Patient in Autistic Disorder Study

Earlier this month, Scioto Biosciences, Inc. began their Phase Ib clinical trial of SB-121 for the treatment of Autistic DIsorder (AD). 

Read more

Celdara Medical Secures Funding to Develop an Adjuvanted Universal Flu Vaccine

Celdara Medical, LLC today announced that the National Institute of Allergy and Infectious Disease (NIAID) of the National Institutes of Health (NIH) has awarded a two-year Small Business Innovation Research (SBIR) contract to fund the development of the novel, parasite-derived, antigen-sparing protein adjuvant ASP-1 for flu vaccines.

Read more

Scioto Biosciences Receives Series B Investment from Genome & Company

Scioto Biosciences announced today the closing of a strategic investment of up to $26.5M from Genome & Company and other investors to join in an upcoming tranche. Genome & Company is a leading microbiome company with headquarters in South Korea. The deal gives Genome & Co a majority stake in Scioto and expands its presence into the US.

Read more

Precision Medicine Leader Dennis H. Langer, M.D., J.D. Joins Javelin Oncology’s Board of Directors

Javelin Oncology, Inc. announced today that the company has named Dennis H. Langer, M.D., J.D. to the company’s board of directors as an independent director. Dr. Langer has served as a director of several public and private health care companies, and served in leadership roles in several pharmaceutical, biotechnology and diagnostic companies.

Read more

Javelin Oncology Hires Steven Yecies as Chief Executive Officer

Javelin Oncology announced today that the company has hired Steven Yecies as Chief Executive Officer. Yecies brings 30 years of experience as an accomplished senior executive, consultant, and investor in the healthcare and life sciences industry.

Read more

Virtici ASCEND participant company, Inimmune, raises $22 Million in Series A Funding Led by Two Bear Capital

Inimmune, www.inimmune.com, a biotechnology company developing immune therapies and components for more effective vaccines, announced today that it raised $22 million in Series A funding. 

Read more